Premium
Burden of serious fungal infections in Mexico
Author(s) -
CorzoLeón D. E.,
ArmstrongJames D.,
Denning D. W.
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12395
Subject(s) - medicine , intensive care medicine , environmental health , microbiology and biotechnology , biology
Summary Serious fungal infections ( SFI s) could be more frequent than are recognised. Estimates of the incidence and prevalence of SFI s are essential in order to identify public health problems. We estimated the rates of SFI s in Mexico, following a methodology similar to that used in prior studies. We obtained information about the general population and populations at risk. A systematic literature search was undertaken to identify epidemiological reports of SFI s in Mexico. When Mexican reports were unavailable, we based our estimates on international literature. The most prevalent SFI s in Mexico are recurrent vulvovaginal candidiasis (5999 per 100 000) followed by allergic bronchopulmonary aspergillosis (60 per 100 000), chronic pulmonary aspergillosis (15.9 per 100 000), fungal keratitis (10.4 per 100 000), invasive candidiasis (8.6 per 100 000) and SFI s in HIV (8.2 per 100 000); coccidioidomycosis (7.6 per 100 000), IA (4.56 per 100 000). These correspond to 2 749 159 people affected in any year (2.45% of the population), probably >10 000 deaths and 7000 blind eyes. SFI s affect immunocompromised and healthy populations. Most are associated with high morbidity and mortality rates. Validation of these estimates with epidemiological studies is required. The burdens indicate that an urgent need to improve medical skills, surveillance, diagnosis, and management of SFI s exists.